None listed
Conditions
Interventions
Drug : Dulaglutide is a glucagon-like peptide-1(GLP-1) receptor agonist and is one of the treatments for type 2 diabetes. It is administered by subcutaneous injection method and self-injects are avail
Sponsors
Korea University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients are eligible to be included in the study only if they meet all of the following criteria: 1. Have been diagnosed with type 2 diabetes mellitus, and 2. are over 20 years old and under 70 years old, and 3. Have HbA1c>7% despite taking two or more oral hypoglycemic agents including metformin and sulfonylurea, or despite the administration of two or more hypoglycemic agents including basal insulin for at least 3 months
Exclusion criteria
Exclusion criteria: Patients will be excluded from study enrollment if they meet any of the following criteria at screening: 1. Have type 1 diabetes mellitus (T1DM) 2. Have any of the following conditions: acute or chronic hepatitis, liver cirrhosis, or chronic kidney disease with estimated glomerular filtration rate <30 mL/min/1.73m2, or congestive heart failure 3. Have a history of psychiatric disorder or untreated malignancy 4. Have evidence of a active autoimmune abnormality (for example, lupus or rheumatoid arthritis) or active infectious disease, or chronic obstructive pulmonary disease. 5. Have received systemic glucocorticoids for 1 week or more within 6 months 6. Have been treated with weight loss drugs within 6 months 7 Have been treated with GLP-1 agonists within 6 months 8. are pregnant or lactating women or those who plan to conceive during the study or within 3 months of the end of the study. 9. Have body mass index < 18.5 kg/m2 10. Have familial or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 11. Had acute or chronic pancreatitis any time prior to study entry
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the mean changes in HbA1c levels | — |
Secondary
| Measure | Time frame |
|---|---|
| the mean changes in ectopic fat (visceral fat, intrahepatic fat, intrapancreatic fat) amounts;the mean changes in body mass index levels;the mean changes in waist circumferences;the mean changes in food craving scores;the mean changes in betatrophin levels | — |
Countries
Korea, Republic of
Contacts
Public ContactJi Hee Yu
Korea University Ansan Hospital
Outcome results
None listed